In this regard, targeting sphingolipid metabolism, through the inhibition of SMS1 or S1PRs, may be of potential relevance to prevent NLRP3 inflammasome activation, which plays a central role in NASH progression [9,104,126]. The gene discussed is SGMS1; the disease is metabolic dysfunction-associated steatohepatitis.